VANCOUVER, British Columbia, Jan. 12, 2017 (GLOBE NEWSWIRE) — PreveCeutical Medical Inc.
(“PreveCeutical”, or the “Company”), a health and wellness company
focused on utilizing nature and science for the benefit of health
conscious consumers, announces it has closed a debt financing, a
revolving convertible line of credit, for $1,000,000 CAD from non-arms’
length parties (the “Loan”), Stephen and Kimberly Van Deventer who are
current Directors of the Company (the “Lenders”). Proceeds from the
financing shall be used for product and market development, and for
general corporate purposes.

In consideration for the Loan,
the Company has agreed to pay simple interest of 5.0% per annum, and the
loan can be paid off at any time with no penalty to the Company.
Additionally, at the discretion of the Lenders, the outstanding balance
of the Loan and interest is convertible to common shares at a deemed
price of $0.50 CAD per share.

About PreveCeutical
For more information about PreveCeutical, please visit www.preveceutical.com, follow us on Twitter: https://twitter.com/preveceuticals, or on Facebook: www.facebook.com/Preveceutical

On Behalf of the Board,

“Stephen Van Deventer”
Chairman & CEO

This
news release may contain forward-looking statements, including without
limitation, future operations of PreveCeutical Medical Inc. (the
“Company”). Forward-looking statements address future events and
conditions and therefore involve inherent risks, uncertainties and
assumptions. Forward-looking statements consist of statements that are
not purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future. Such information
can generally be identified by the use of forwarding-looking wording
such as “may”, “expect”, “estimate”, “will”, “anticipate”, “intend”,
“believe” and “continue” or the negative thereof or similar variations.
Actual results may differ materially from those currently anticipated
in such statements and the Company undertakes no obligation to update
such statements, except as required by law. While such estimates and
assumptions are considered reasonable by the management of the Company,
they are inherently subject to significant business, economic,
competitive and regulatory uncertainties and risks. In particular, there
is no guarantee that the Blue Scorpion Venom will effectively treat or
cure cancer or other diseases. Accordingly actual results may differ
materially from those currently anticipated in such statements.

The
Company has made numerous assumptions regarding, among other things:
the effectiveness of its products; the demand for its products and the
stability of economic and market conditions. Investors are cautioned
that all forward-looking statements involve risks and uncertainties,
including: that the Company may lose or abandon or may fail to receive
necessary licenses and permits; labour disputes; the Company may not
receive the necessary regulatory approvals for its products; the
increase in cost estimates and the potential for unexpected costs and
expenses; general economic and market conditions may worsen; market
shifts may require a change in strategic focus; the Company may not be
able to raise additional funds when necessary; litigation; and
competition. Factors that could cause actual results to differ
materially from those in forward looking statements include continued
availability of capital and financing and general economic, market or
business conditions, consumer sentiment towards the Company’s products,
competition, the failure of counterparties to perform their contractual
obligations, and fees charged by service providers.

All
forward-looking statements concerning the Company’s future plans and
operations, including management’s assessment of the Company’s
operational expectations or beliefs may be subject to certain
assumptions, risks and uncertainties beyond the Company’s control.
Investors are cautioned that any such statements are not guarantees of
future performance and that actual performance and financial results may
differ materially from any estimates or projections. Accordingly,
readers should not place undue reliance on forward-looking statements
and information, which are qualified in their entirety by this
cautionary statement. There can be no assurance that forward-looking
information, or the material factors or assumptions used to develop such
forward looking information, will prove to be accurate.

PreveCeutical Medical Inc.
Suite 605 – 815 Hornby Street,
Vancouver, B.C., V6Z 2E6, Canada
www.preveceutical.com
1 (866) 398-1288


In the interest of full disclosure, we call the reader’s
attention to the fact that Equities.com, Inc. is compensated by the
companies profiled in the Spotlight Companies section. The purpose of
these profiles is to provide awareness of these companies to investors
in the micro, small-cap and growth equity community and should not in
any way be considered as a recommendation to buy, sell or hold these
securities. Equities.com is not a registered broker dealer, investment
advisor, financial analyst, investment banker or other investment
professional. We are a publisher of original and third party news and
information. All profiles are based on information that is available to
the public. The information contained herein should not be considered to
be complete and is not guaranteed by Equities.com to be free from
misstatement or errors. The views expressed are our own and not intended
to be the basis for any investment decision. Readers are reminded to do
their own due diligence when researching any companies mentioned on
this website. Always bear in mind that investing in early-stage
companies is risky and you are encouraged to only invest an amount that
you can afford to lose completely without any change in your lifestyle.
Equities has been compensated with cash, common shares and/or warrants
for market awareness services provided.